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OBJECTIVES We investigated the prevalence of lamin A/C (LMNA) gene defects in familial and sporadic
dilated cardiomyopathies (DCM) associated with atrioventricular block (AVB) or increased
serum creatine-phosphokinase (sCPK), and the corresponding changes in myocardial and
protein expression.
BACKGROUND It has been reported that familial DCM, associated with conduction disturbances or variable
myopathies, is causally linked to LMNA gene defects.
METHODS The LMNA gene and myocardial ultrastructural and immunochemical changes were
analyzed in 73 cases of DCM (49 pure, 15 with AVB [seven familial, eight sporadic], 9 with
increased sCPK), four cases of familial AVB and 19 non-DCM heart diseases. The normal
controls included eight heart donor biopsies for tissue studies and 107 subjects for LMNA
gene studies.
RESULTS Five novel LMNA mutations (K97E, E111X, R190W, E317K, four base pair insertion at
1,713 cDNA) were identified in five cases of familial autosomal dominant DCM with
AVB (5/15: 33%). The LMNA expression of the myocyte nuclei was reduced or absent.
Western blot protein analyses of three hearts with different mutations showed an
additional 30-kDa band, suggesting a degrading effect of mutated on wild-type protein.
Focal disruptions, bleb formation and nuclear pore clustering were documented by
electron microscopy of the myocyte nuclear membranes. None of these changes and no
mutations were found in the nine patients with DCM and increased sCPK or in the
disease and normal controls.
CONCLUSIONS The LMNA gene mutations account for 33% of the DCMs with AVB, all familial autosomal
dominant. Increased sCPK in patients with DCM without AVB is not a useful predictor of
LMNA mutation. (J Am Coll Cardiol 2002;39:981–90) © 2002 by the American College
of Cardiology Foundation
Lamins A and C are major constituents of the nuclear
lamina, the proteinaceous meshwork underlying the inner
nuclear membrane (1). Defects in the lamin A/C (LMNA)
gene (2) have been causally linked to four different diseases
with 42 reported mutations (3–18) (Fig. 1):
• dilated cardiomyopathy (DCM) with conduction system
disease (3,4) or variable myopathy (7),
• limb girdle muscular dystrophy (LGMD) (8),
• autosomal dominant variant of Emery-Dreifuss muscular
dystrophy (EDMD) (8–13),
• autosomal dominant partial lipodystrophy (15–17).
Together with emerin defects (19), lamin A/C defects
constitute the first entries in the new field of nuclear
envelopathies in which, with the exception of two familial
DCMs (5,6) and partial lipodystrophy (15–17), atrioven-
tricular conduction disease is a major cardiac marker (3,4).
On the basis of the cardiac phenotypes reported as being
associated with LMNA defects, we hypothesized that atrio-
ventricular disturbances or increased serum creatine-
phosphokinase (sCPK) potentially related to subclinical
myopathy may be a useful guide for LMNA analysis in
patients with DCM.
The aims of this study were: 1) to assess the prevalence of
LMNA gene defects in patients with DCM, associated or
not with atrioventricular block (AVB) or increased sCPK,
and patients with familial AVB without DCM; and 2) to
characterize the pathological changes and protein expression
in the myocardium of patients carrying LMNA defects.
METHODS
Clinical and control series. Our Institutional Review
Committee approved the study, and the patients and rela-
tives gave their written informed consent.
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The disease series consisted of:
• 15 patients with DCM and first degree AVB: seven
familial (five autosomal dominant and two sib pairs) and
eight sporadic. Dilated cardiomyopathy was defined as
familial when two or more members were found to be
affected after clinical, electrocardiographic and echocar-
diographic evaluation of all of the informed and consent-
ing relatives who accepted the Familial DCM Screening
Program (20) or when clinical and pathological records
were provided for deceased affected members.
• nine patients with DCM, no AVB, but persistent sCPK
190 mU/ml (two or more resting determinations)
unrelated to dystrophin, emerin or dystrophin-associated
glycoprotein defects and without clinically overt myop-
athy. Increased sCPK levels were considered a possible
marker of “subclinical” myopathy.
The disease control series included:
• 49 patients with familial (n  25, eight with left bundle
brunch block [LBBB]) or sporadic (n  24, eight with
LBBB) DCM without AVB or increased sCPK;
• four patients with familial AVB, without DCM in the
probands or relatives;
• nine patients with valvular heart disease and 10 with
ischemic heart disease, four with and 15 without AVB.
The normal control series included:
• 107 blood donors with normal electrocardiograms and
sCPK (for LMNA gene screening);
• eight endomyocardial biopsies (EMB) from normal do-
nor hearts before transplantation (for immunohistochem-
ical and Western blot LMNA analysis).
Dilated cardiomyopathy was diagnosed on the basis of
World Health Organization criteria (21). The informed and
consenting relatives of all of the DCM patients underwent
a clinical examination, 12-lead electrocardiography, echo-
cardiography and sCPK determination (20). The neuro-
muscular assessment of probands and relatives was based on
a detailed clinical history, physical examination and sCPK
Abbreviations and Acronyms
AVB  atrioventricular block
DCM  dilated cardiomyopathy
DHPLC  denaturing high-performance liquid
chromatography
EDMD  Emery-Dreifuss muscular dystrophy
EMB  endomyocardial biopsy
LBBB  left bundle brunch block
LGMD  limb girdle muscular dystrophy
LMNA  lamin A/C
NYHA  New York Heart Association
sCPK  serum creatine-phosphokinase
Figure 1. Localization of published lamin A/C (LMNA) mutations and corresponding phenotypes; the gray square contains the mutations found in this
study. A-V  atrioventricular; DCM  dilated cardiomyopathy; EDMD  Emery-Dreifuss muscular dystrophy; FPL  familial partial lipodystrophy;
LGMD  limb girdle muscular dystrophy.
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and serum lactate determinations. Clinical and pathological
records were obtained for deceased affected relatives.
A Fisher exact test was used to compare the proportion of
the mutations among phenotype groups and to assess the
statistical significance of the results.
Mutation screening. The 12 exons of the LMNA gene
were amplified from peripheral blood-derived genomic
DNA by means of polymerase chain reaction, using primers
derived from intronic sequences (14). The polymerase chain
reaction fragments were analyzed by means of denaturing
high-performance liquid chromatography (DHPLC)
(Transgenomic, San Jose, California) using the Wave DNA
Fragment Analysis System (22). The fragments with a
heteroduplex conformation were purified (QIAquick Kit,
Qiagen, Santa Clarita, California) and then sequenced using
a BigDye-terminator cycle sequencing system (ABI PRISM
377, Applied Biosystem, Foster City, California).
Endomyocardial biopsy. Endomyocardial biopsy was per-
formed in all patients according to the standard procedure
(23), with three to four samples being assigned to light
microscopy and routine immunostaining for inflammatory
cells, dystrophin and the dystrophin-associated glycoprotein
complex, emerin, LMNA, actin and desmin (24,25). Two
samples were processed for ultrastructural study and ana-
lyzed using a Zeiss EM902 electron microscope.
Light microscopy immunostaining for LMNA and
emerin. Formalin-fixed paraffin-embedded biopsy sections
were reacted with antibodies against LMNA (Chemicon
International, Inc., Temecula, California, mouse anti-
human lamin A  C monoclonal Ab, 1:50) and emerin
(Novocastra, Newcastle, United Kingdom, mouse anti-
emerin monoclonal Ab, 1:100) using the avidin-biotin
complex-peroxidase method, diaminobenzidine tetrahydro-
chloride as chromogen and 4,6 diamidino-2-phenylindole
for nuclear staining (23,25). The anti-lamin antibody binds
to an epitope between amino acids 464 and 572, which is
shared by both lamin A and C. The positive controls
included EMBs from normal heart donors and patients with
DCM known to be free of LMNA defects, and heart
samples from transplanted patients with valvular and isch-
emic disease. The negative controls consisted of sections
incubated without the primary antibody. All of the reactions
were performed using control procedures.
Western blot. One-dimensional electrophoresis was per-
formed on proteins extracted from three hearts excised at
transplantation (patients A-II-1, A-II-2 and B-III-1) (25).
The protein-loading concentration was determined using
the bicinchoninic acid protein assay kit (Sigma Aldrich, St.
Louis, Missouri) (26), and 25 g of each sample was run on
10% polyacrylamide gel (SDS PAGE). After electrophore-
sis, the gels were transferred to nitrocellulose sheets that
were immunostained, first with anti-lamin A/C monoclonal
primary antibody and then with a secondary antibody
conjugated with alkaline phosphatase (25).
RESULTS
Genetic studies. A unique sequence variant was identified
in five unrelated probands with familial autosomal domi-
nant DCM and AVB (5/15: prevalence 33%) (Table 1, Fig.
2). No sequence variants were found in the two sib-pairs or
the eight cases of sporadic DCM with AVB, in the nine
cases of DCM with increased sCPK (mean: 521.5 254.27
mU/ml; range: 218 to 994) or any of the disease or normal
controls (p  0.001). Each variant was independently
confirmed by means of automated sequencing, restriction-
enzyme digestion for Lys97Glu (-Sty I) and Glu111Stop
(-Mnl I), and DHPLC. None of these five variants was
found in 107 normal subjects, thus excluding the possibility
that they are common polymorphisms. All five variants
affect amino acids shared by lamin A and C: Lys97Glu and
Glu111Stop are encoded in exon 1 (coil 1b, rod domain),
Arg190Trp in exon 3 (coil 1b, rod domain), Glu317Lys in
exon 6 (coil 2, rod domain); the ctgc insertion at
2869cDNA in exon 9 (globular tail) predicts a protein of
525 normal followed by 34 new amino acids. Glu111Stop
predicts a truncated soluble protein of 110 amino-acids,
with a molecular weight of 12 KD and an average hydro-
phobicity of 0.756364.
The five sequence variants were considered to be disease-
causing mutations because:
• They were found in affected family members but not in
unaffected relatives more than 40 years of age. Given the
late penetrance of the defects (phenotype onset ranging
from 27 to 44 years), the age of 40 was considered a
reasonable upper limit for the expected expression of the
mutation.
• They changed the charges (n  3) and predicted major
rearrangements (n  2) of the mutated protein.
• They all affected highly conserved residues.
Clinical data. The clinical data, disease evolution and
follow-up of the probands and relatives are shown in Table
1. Of the 33 family members with available clinical data, 16
were affected by DCM with AVB, three had AVB (n  2)
or left ventricular dilation (n  1), and 14 were unaffected.
DNA was available for 25 subjects (23 living, two dead) but
not for six dead, one living patient and for one healthy
family member. Eighteen of the 25 tested subjects are
heterozygous for LMNA mutations, including nine affected
by DCM with AVB, one with asymptomatic left ventricular
dilation and two with an isolated AVB (one requiring
pacemaker implantation). Of the remaining six heterozy-
gous subjects, three children age 7, 12 and 13 years are free
from signs and symptoms, and three young adults age 25, 29
and 39 years have premature ventricular beats.
The natural history of the disease in the five families with
mutations was assessed on the basis of the clinical monitor-
ing program for familial cardiomyopathies. Of the 18 living
family members tested, seven have been followed up for
33.71  8.77 months (Table 1). In the probands, the onset
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of the disease occurred in early middle age (mean: 37 years;
range: 27 to 44). The AVB was documented as preceding
the DCM in 3/5 probands and their relatives and diagnosed
at the same time as the DCM in two. Of the eight living
patients, four have undergone, and one is waiting for, a
heart transplantation; two are stable in New York Heart
Association (NYHA) class II and one in NHYA class III.
The clinical evolution in the five families was different
(Table 1). The living patients of family B had rapidly
evolving disease; one underwent transplantation within
three years of onset, and one is waiting for transplantation
three months after onset. In the patients of families A, C
and E, there was a long interval between the onset of AVB
and DCM. Sudden death occurred in only one patient of
family E (but at the age of 70 years), and life-threatening
ventricular arrhythmias were recorded only in the proband
Table 1. Families With Lamin A/C Gene Mutations: Clinical Data of Probands and Their Relatives
Patient Mutation
Onset, Evolution,
Follow-Up (age)
sCPK
(mU/ml) Electrocardiogram
PQ
(m/s)
LVEDD/
ESD (mm)
LVFS
(%)
LVEDV/
ESV (ml)
LVEF
(%)
A-II-1 E111X Onset: 43 y Nt Sinus bradycardia
53 y 65 III° AVB3PM 73/61 16 20
55 y 70 PM 71/63 11 280/225 20
56 y 68 PM 73/69 5 310/260 18
Transplantation: 57 y 72
A-II-2 E111X Chance finding: 43 y 49 III° AVB3PM Normal Normal Normal Normal
47 y 54 PM 69/63 8 286/210 26
53 y 51 PM 74/67 9 315/240 20
Transplantation: 56 y
A-III-1 — Baseline: 33 y 48 Normal 168 47/33 30 86/33 61
35 y 44 Normal 167 51/34 33 100/53 58
A-III-2 E111X Baseline: 25 y 123 PVC 178 51/26 48 122/52 58
28 y 99 PVC 187 51/33 36 128/61 55
A-III-3 — Baseline: 30 y 88 Normal 165 43/23 47 79/30 62
32 y 73 Normal 164 46/27 40 84/33 60
A-III-4 E111X Baseline: 25 y 73 Normal 146 42/24 44 63/28 55
28 y 76 Normal 153 49/31* 38 63/25 65
B-III-1 K97E Onset: 30 y Nt III° AVB 58/NA 35
31 y 245 III° AVB  LBBB3PM 56/48 14 193/141 26
Transplantation: 32 y 250
B-III-2 K97E Baseline: 29 y 91 PVC 160 52/31 40 68
B-III-3 K97E Onset: 27 y 194 I° AVB  LBBB 240 74 67 299/250 15
B-IV-1 — Baseline: 4 y NA Normal Normal
C-II-2 Ins: ctgc, 2,869 Onset: 33 y Nt II° AVB  LBBB Normal
51 y Nt II° AVB  LBBB Increased Increased Decreased
56 y Nt PM 62/41 33 34
58 y 52 PM 65/53 18 160/128 20
Transplantation: 58 y
C-II-1 — Baseline: 58 y 132 LAFB 148 47/35 26 120/57 52
61 y 123 LAFB 148 49/27 45 94/31 67
C-III-1 Ins: ctgc, 2,869 Baseline: 34 y 341 I° AVB  PAC 387 56/40 30 180/60 67
38 y 494 PM 60/42* 30 178/71 60
C-III-2 Ins: ctgc, 2,869 Baseline: 31 y 260 Normal 186 51/33 34 93/26 72
34 y 207 Normal 200 50/31 39 106/40 62
D-I-2 R190W Deceased at 47 y DCM†
D-II-1 R190W Onset: 41 y 180 I° AVB  RBBB  LAFB 239 60/53 11 250/178 28
42 y 185   Atrial flutter 240
D-II-2 R190W Baseline: 39 y 105 PVC 154 44/31 30 125/53 60
D-III-1 R190W Baseline: 13 y 117 Normal 152 42/26 38 87/30 65
D-III-2 R190W Baseline: 7 y 75 Normal 135 38/18 52 53/23 55
D-III-3 — Baseline: 7 y 54 Normal 117 40/25 37 70/34 52
D-III-4 R190W Baseline: 12 y 213 Normal 168 42/28 33 82/25 65
E-II-2 E317K Deceased at 69 y PM DCM†
E-III-2 E317K Onset: 44 y I° AVB
64 y I° AVB  LBBB
64 y 90 III° AVB  LBBB3PM 331/182 40
E-IV-2 — Baseline: 35 y 63 Normal 172 47/30 36 105/38 64
E-IV-3 — Baseline: 32 y 47 Normal 170 43/31 36 110/40 63
*LVEDD  112% of the predicted value corrected for age and body surface area; †from autopsy specimens.
AVB  atrioventricular block; Ins: ctgc, 2,869  insertion of ctgc at position 2.869; LAFB  left anterior fascicular block; LBBB  left bundle branch block; LVEDD/ESD  left
ventricular end-diastolic/end-systolic diameter; LVEDV/ESV  left ventricular end-diastolic and end-systolic volume; LVEF  left ventricular ejection fraction; LVFS  fractional
shortening; NA  not available; Normal  the cardiological report; Nt  not tested; PAC  premature atrial complexes; PM  pacemaker; PVC  premature ventricular
complexes; RBBB  right bundle branch block; sCPK  serum creatine-phosphokinase; y  year.
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Figure 2. 1) Family A: mutation E111X; 2) Family B: mutation K97E; 3) Family C: CTGC insertion at 2,869 of the cDNA; 4) Family D: mutation
R190W; 5) Family E: mutation E317K. Filled symbols patients; open symbols non-affected subjects; question marks within symbols non-proven
affected subjects. Small squares within symbols  atrioventricular block (upper left), left ventricular dilation (upper right). Diagonal lines  death. The
probands are indicated by arrows. The presence () or absence () of the mutation is indicated for the genetically tested family members. Chromatograms
below each pedigree demonstrate the heterozygous mutations.
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of family C. In family D, the proband developed the disease
at the age of 41 years, and his affected mother died at age 47.
The neuromuscular assessment excluded myopathy in all
of the probands and affected relatives, who had normal
serum lactate levels (11.70  3.19; range: 19.50 to 7.20).
The levels of sCPK were minimally high (245, 341, 260 and
213 mU/ml, respectively) in one proband and three non-
penetrant carriers.
Pathological studies. Light microscopy of the EMBs re-
vealed aspecific myocyte damage and interstitial fibrosis.
The ultrastructural study showed “delamination,” focal rup-
tures, blebs and nuclear pore clustering of the myocyte
nuclear membranes (Fig. 3). These defects were not ob-
served in the EMBs of the non-mutated DCM patients.
Immunostaining with anti-LMNA antibodies showed
normal staining of interstitial and vascular cell nuclei (with-
in sample control) and the loss of staining in a number of
myocyte nuclei (Fig. 4). Anti-emerin antibodies regularly
immunostained nuclear membranes but no cytoplasmic
compartments.
The atrioventricular junction of the three hearts excised at
transplantation showed fibrosis, fatty infiltration and degen-
erative myocyte changes (Fig. 5). Western blot analyses of
the proteins extracted from the hearts of patients carrying
the E97K and E111X mutations showed reduced protein
content (particularly lamin C) and an additional 30 kDa
band specifically immunostained by the antibody (Fig. 6,
lanes 2, 3 and 5), which was absent in the normal and
disease controls (Fig. 6, lanes 1 and 4).
DISCUSSION
We documented a high prevalence of LMNA gene defects
in our DCM patients with AVB (5/15: 33%), all of whom
had familial autosomal dominant diseases. The correspond-
ing immunopathological phenotype was characterized by
defective LMNA immunostaining, an abnormal 30 kDa
LMNA-positive band and disruption of the nuclear mem-
brane of cardiac myocytes. Our hypothesis that increased
Figure 3. Electron micrographs showing nuclear membrane damage (arrow) (a), bleb formation (arrow) (b) and c) and nuclear pore clustering (arrow) (d)
in cardiac myocytes from myocardial samples of patients A-II-1 (a), B-III-1 (b), C-II-2 (c) and D-II-1 (d) (uranyl-acetate, lead citrate). Bar scales 
0.6 m.
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sCPK might be a marker of LMNA defects in DCM
patients without AVB was not confirmed.
Pathological and immunochemical findings. To the best
of our knowledge, this is the first description of ultrastruc-
tural nuclear membrane damage associated with LMNA
gene defects in DCM patients with AVB. Similar nuclear
envelope disruptions, discontinuities of the inner face of the
nuclear envelope, and nuclear pore clustering have been
observed in patients with X-linked EDMD (27), lamin A
null mice (28) and the Drosophila lamin Dm0 mutant (29).
According to Hutchison et al. (30), the nuclear membrane
damage and lamina fragility could develop into physical cell
disruption leading to myocyte death and tissue damage. In
skeletal muscle, it is likely that only a large number of
altered nuclei can compromise individual multinucleated
fibers, whereas in cardiac muscle, the loss of individual
mono-nucleated myocytes in adults is cumulative and even-
tually leads to AVB and heart failure when the number of
affected myocytes is sufficient to cause the phenotypes (30).
The extension of myocyte damage in nodal versus left
ventricular myocardium could partly explain the earlier
occurrence of AVB than left ventricular dysfunction ob-
served in three of our five probands. The defective LMNA
immunostaining of myocyte nuclear membranes associated
with LMNA mutations contrasts with the normal immu-
nostaining of the nuclei of interstitial and vascular cells.
This different pattern could be related to stage-and tissue-
specific LMNA expression and fits with the most intriguing
and unresolved issue concerning patients with LMNA
defects, that is, the selective involvement of muscular,
cardiac and fat cells (30). Furthermore, the low molecular
weight fragment (about 30 kDa) found only in the patients
carrying mutated (K97E) or truncated (E111X) versions of
the protein suggests that abnormal LMNAs may induce
degradation of the normal allele product. This mechanism
may contribute to the dominant negative effect of the
mutated on the wild-type LMNA. Dominant negative
proteins have been shown capable, in vitro, of disrupting
preformed LMNA-types (31). The absence of lamin im-
munolabeling in cardiac myocytes and the presence of a low
molecular weight fragment suggest that mutated LMNAs
increase degradation of the wild-type proteins. Interest-
ingly, cells that are not terminally differentiated and are
actively cycling, such as fibroblasts, endothelial and smooth
muscle cells, still contain enough LMNAs to be detected by
immunostaining. A-type-lamin protein levels increase with
the terminal differentiation and growth arrest, while the
corresponding mRNA levels significantly decrease, suggest-
Figure 4. Lamin A/C immunostain (a, c, e) and corresponding DAPI nuclear stain (b, d, f). (a, b) Normal heart sample. (c, d) Control dilated
cardiomyopathy without (LMNA) mutation; all myocyte and interstitial-vascular nuclei are immunostained by the anti-LMNA antibody. (e, f)
Endomyocardial biopsy from patient A-II-1; note the absence of LMNA immunostain in some myocyte nuclei and positive interstitial-vascular cell nuclei
(Avidin-Biotin Complex, DAPI nuclear stain; a and b, 40; c to f, 110).
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ing a role for transcriptional and post-transcriptional mech-
anisms in controlling LMNA levels (32). If the mutated
LMNA induces an increased degradation of the wild-type
protein, terminally differentiated cells such as cardiac myo-
cytes will be progressively depleted of type-A-lamins. Fur-
thermore, the low LMNA mRNA levels present in those
cells will not be able to sustain a proportional increase in
translation of LMNA mRNA to compensate for the in-
creased degradation rate. On the contrary, in cycling cells,
the higher mRNA levels (32) will partially compensate the
increased degradation of the protein induced by the mutant.
Genotype-phenotype correlation. The genotype-phenotype
correlation seems to be quite complex: neither the involvement
of given protein domains nor the type of mutation character-
istically recurs in DCM with conduction disease. One of our
five mutations (E111X in coil 1b) predicts a very small (12
kDa) truncated soluble peptide. Two of the other four muta-
tions (K97E and R190W) are in coil 1b, which is part of the
region necessary for lamin B-LMNA interactions and tet-
ramere formation (27). One (E317K) is in a segment of coil 2
that does not interact with proteins or chromatin, and one
(insertion ctgc 2869 cDNA) is in a tail domain of the protein
essential for LMNA-emerin interactions (30). The observed
differences in clinical manifestations and disease evolu-
tion in our families (the mildest phenotype is in family E
with the E317K LMNA mutation) suggest that the
Figure 5. Atrioventricular junction of patients A-II-1 and B-III-1: fibrosclerosis and fibrofatty degeneration (Movat Pentachrome stain, 10).
Figure 6. Western blot showing lamin A and lamin C bands and the additional 30 kDa immunoreacting band corresponding to an abnormal small peptide
comprising the epitope recognized by the antibody. This band is identical in patients with different lamin A/C (LMNA) mutations (lane 2: A-II-1; lane
3: B-III-1; lane 5: A-II-2) but absent in normal controls (lane 1) and patients with dilated cardiomyopathy unrelated to LMNA defects (lane 4).
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impaired nuclear lamina interactions may play a role in
the phenotype.
The hypothesis of a complex genotype/phenotype corre-
lation is strengthened by the informative family #1 de-
scribed by Bonne et al. (14), in which the same mutation
co-segregated with both DCM and EDMD, and by the
family described by Brodsky et al. with coexistent LGMD,
EDMD and DCM (7). In our series, none of the nine
DCM patients with increased sCPK, but without AVB, had
LMNA gene defects; the B-III-1 proband, and subjects
C-II-1, C-II-2 and D-III-4, who had slightly raised sCPK
levels, had no contractures and did not show any clinical
signs of myopathy. The size of the pedigrees does not
explain these inconsistencies. For example, of the four sons
of EDMD patient III-11 reported by Bonne et al. (14), two
had EDMD (IV-13 and 14), and two had DCM (IV-15
and 16). It is therefore likely that factors other than LMNA
mutations influence the phenotype, such as tissue-specific or
systemic modifier gene expression, and the late and variable
penetrance of the defects.
Role of AVB in molecular diagnosis. In the cardiological
setting, the AVB associated with DCM is a reliable marker
for LMNA gene molecular screening (3,4). In our series,
none of the DCM patients without AVB had any LMNA
defects, and none of their EMBs showed the ultrastructural
and immunostaining defects observed in the five patients
with LMNA gene mutations. The absence of LMNA
mutations in our four families with isolated AVB does not
exclude the indication for LMNA screening, as AVB
preceded DCM diagnosis in three of our five families
(Families A, C and E).
Genetic counseling. A major issue in genetic counseling is
the risk of sudden death in carriers of LMNA mutation
(3,4,33). In our series, sudden death was recorded in only
one affected family member of the oldest patient (Family E),
but life-threatening arrhythmias were recorded in Patient
C-I-2. The currently available data do not clarify whether
mutated subjects with normal electrocardiograms and ven-
tricular function risk sudden death. This information would
be essential for counseling and, potentially, for preventing
fatal events.
In summary, LMNA gene mutations accounted for 33%
of our cases of DCM with AVB, all of which were familial
autosomal dominant DCMs. Increased sCPK levels in
DCM patients without AVB were not useful in predicting
LMNA mutations. The cardiac immunopathological phe-
notype was characterized by abnormal/defective nuclear
LMNA expression and nuclear membrane disruption.
Nucleotide numbers: cDNA sequence GeneBank Acces-
sion No #M13451 (lamin C mRNA), L12399, Version
GI:12399.3-6960369 (LMNA DNA exon 1), L12400
(LMNA DNA exon 2), L12401 (DNA exons 3 to 12),
M13452 (lamin A, mRNA). Neutral polymorphisms found
in our overall series: T995C, T1472C, C1832T (known)
and C185T, G1314A (novel).
Acknowledgments
The authors are indebted to the family members for their
participation and collaboration and would like to thank Dr.
Claudia Specchia, Department of Health Sciences, Univer-
sity of Genova, Italy, for statistical analysis.
Reprint requests and correspondence: Dr. Eloisa Arbustini,
Molecular Diagnostic Laboratory, Transplant Research Area,
I.R.C.C.S. Policlinico San Matteo, Via Forlanini 16, 27100 Pavia,
Italy. E-mail: e.arbustini@smatteo.pv.it.
REFERENCES
1. Krohne G, Benavente R. The nuclear lamins: a multigene family of
proteins in evolution and differentiation. Exp Cell Res 1986;162:1–10.
2. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure,
assembly, and interactions. J Struct Biol 1998;122:42–66.
3. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod
domain of the lamin A/C gene as causes of dilated cardiomyopathy
and conduction-system disease. N Engl J Med 1999;341:1715–24.
4. Jakobs PM, Hanson EL, Crispell KA, et al. Novel lamin A/C
mutation in two families with dilated cardiomyopathy and conduction
system disease. J Card Fail 2001;7:249–56.
5. Genschel J, Baier P, Kuepferling S, et al. A new frameshift mutation
at codon 466 (1397delA) within the LMNA gene. Hum Mutat
2000;16:278.
6. Genschel J, Bochow B, Kuepferling S, et al. An R644C mutation
within lamina A extends the mutations causing dilated cardiomyopa-
thy. Hum Mutat 2001;17:154.
7. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L.
Lamin A/C gene mutation associated with dilated cardiomyopathy
with variable skeletal muscle involvement. Circulation 2000;101:
473–6.
8. Muchir A, Bonne G, van Meegen M, et al. Identification of mutations
in the gene encoding lamins A/C in autosomal dominant muscular
dystrophy with atrioventricular conduction disturbances (LGMD1B).
Hum Mol Genet 2000;9:1453–9.
9. Bione S, Maestrini M, Rivella S, et al. Identification of a novel
X-linked gene responsible for Emery-Dreifuss muscular dystrophy.
Nat Genet 1994;8:323–7.
10. Bione S, Small K, Aksmanovic VMA, et al. Identification of new
mutations in the Emery-Dreifuss muscular dystrophy gene and evi-
dence for genetic heterogeneity of the disease. Hum Mol Genet
1995;4:1859–63.
11. Bonne G, Raffaele di Barletta M, Varnous S, et al. Mutations in the
gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss
muscular dystrophy. Nat Genet 1999;21:285–8.
12. Raffaele di Barletta M, Ricci E, Galluzzi G, et al. Different mutations
in the LMNA gene cause autosomal dominant and autosomal recessive
Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000;66:
1407–12.
13. Felice KJ, Schwartz RC, Brown CA, Leicher CR, Grunnet ML.
Autosomal dominant Emery-Dreifuss dystrophy due to mutations in
rod domain of the lamin A/C gene. Neurology 2000;55:275–80.
14. Bonne G, Merceni E, Muchir A, et al. Clinical and molecular genetic
spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy
due to mutation of the lamina A/C gene. Ann Neurol 2000;48:170–
80.
15. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin
A/C, is mutated in partial lipodystrophy. Nat Genet 2000;24:153–6.
16. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian
kindreds with Dunningan-type familial partial lipodystrophy. Hum
Mol Genet 2000;9:109–12.
17. Speckman RA, Garg A, Du F, et al. Mutational and haplotype
analyses of families with familial partial lipodystrophy (Dunningan
variety) reveal recurrent missense mutations in the globular C-terminal
domain of lamin A/C. Am J Hum Genet 2000;66:1192–8.
18. Genschel J, Schmidt HH. Mutations in the LMNA gene encoding
lamin A/C. Hum Mutat 2000;16:451–9.
989JACC Vol. 39, No. 6, 2002 Arbustini et al.
March 20, 2002:981–90 Lamin A/C, Cardiomyopathy and Conduction Disease
19. Cartegni L, Raffaele di Barletta M, Barresi R, et al. Heart-specific
localization of emerin: new insights into Emery-Dreifuss muscular
dystrophy. Hum Mol Genet 2000;6:2257–64.
20. Gavazzi A, Repetto A, Scelsi L, et al. Evidence-based diagnosis of
familial non-X-linked dilated cardiomyopathy: prevalence, inheritance
and characteristics. Eur Heart J 2001;1:73–81.
21. Richardson P, McKenna WJ, Bristow M, et al. Report of the 1995
World Health Organization/International Society and Federation of
Cardiology Task Force on the definition and classification of cardio-
myopathies. Circulation 1996;93:841–2.
22. Oefner PJ, Underhill PA. DNA mutation detection using denaturing
high performance liquid chromatography (DHPLC). In: Dracopoli
NC, Haines JL, Korf BR, et al., editors. Current Protocols in Human
Genetics. New York, NY: Wiley and Sons, 1998, 7.10.1–7.10.12.
23. Arbustini E, Grasso M, Diegoli M, et al. Expression of tumor necrosis
factor in human acute cardiac rejection. Am J Pathol 1991;139:709–
15.
24. Arbustini E, Diegoli M, Morbini P, et al. Prevalence and character-
istics of dystrophin defects in adult male patients with dilated
cardiomyopathy. J Am Coll Cardiol 2000;35:1760–8.
25. Arbustini E, Morbini P, Grasso M, et al. Restrictive cardiomyopathy,
atrioventricular block and mild to subclinical myopathy in patients
with desmin-immunoreactive material deposits. J Am Coll Cardiol
1998;31:645–53.
26. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein
using bicinchoninic acid. Anal Biochem 1985;150:76–85.
27. Fidzianska A, Toniolo D, Hausmanowa-Petrusewicz I. Ultrastructural
abnormality of sarcolemmal nuclei in Emery-Dreifuss muscular dys-
trophy (EDMD). J Neurol Sci 1998;159:88–93.
28. Sullivan T, Escalante-Alcade D, Bhatt H, et al. Loss of A-type lamin
expression compromises nuclear envelope integrity leading to muscular
dystrophy. J Cell Biol 1999;147:913–20.
29. Lenz-Bohme B, Wismar J, Fuchs S, et al. Insertional mutation of the
Drosophila nuclear lamin Dm0 gene results in defective nuclear
envelopes, clustering of nuclear pores, and accumulation of annulate
lamellae. J Cell Biol 1997;137:1001–16.
30. Hutchison CJ, Alvarez-Reyes M, Vaughan OA. Lamins in disease:
why do ubiquitously expressed nuclear envelope proteins give rise to
tissue-specific disease phenotypes? J Cell Sci 2001;114:9–19.
31. Izumi M, Vaughan OA, Hutchinson CJ, Gilbert DM. Head and/or
CaaX domain deletions of lamin proteins disrupt preformed lamin A
and C but not lamin B structure in mammalian cells. Mol Biol Cell
2000;11:4323–37.
32. Pugh GE, Coates PJ, Lane EB, Raymond Y, Quinlan RA. Distinct
nuclear assembly pathways for lamins A and C lead to their increase
during quiescence in Swiss 3T3 cells. J Cell Sci 1997;110:2483–93.
33. Becane HM, Bonne G, Varnous S, et al. High incidence of sudden
death of conduction system and myocardial disease due to lamins A/C
gene mutation. Pacing Clin Electrophysiol 2000;23:1661–6.
990 Arbustini et al. JACC Vol. 39, No. 6, 2002
Lamin A/C, Cardiomyopathy and Conduction Disease March 20, 2002:981–90
